Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology […]

Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications

Maastricht, The Netherlands, 22 June 2015 – Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec® platform, today announced the publication of three articles on CriPec®-based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr. Cristianne Rijcken, founder […]

Cristal Therapeutics announces formation of Scientific Advisory Board

Maastricht, The Netherlands, 22 May 2014 – Cristal Therapeutics, today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni to its new Scientific Advisory Board. Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such […]

Cristal Therapeutics announces appointment of Jeroen Tonnaer as Chief Business Officer

Maastricht, The Netherlands, 21 April 2015 – Cristal Therapeutics, a privately-held life sciences company developing novel nanotherapeutics against cancer and other diseases, by using its patented CriPec® platform announced today the appointment of Jeroen Tonnaer as new Chief Business Officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities. Jeroen obtained an MSc in […]

€6 million in new capital and new CEO

Maastricht, The Netherlands, December 15, 2014 – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding […]

Cristal Therapeutics and Enabling Technologies

You can watch the video using the following link:

Cristal Therapeutics raises additional funding for its lead product CriPec® docetaxel

Maastricht, The Netherlands, July 1, 2013 – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., announces the successful expansion of the financing round initiated by Thuja Capital and BioGeneration Ventures, by adding two additional investors, being Nedermaas Ventures and Innovatie Fonds Limburg. The proceeds of this round will allow Cristal […]

Nedermaas Ventures en Innovatiefonds investeren in Cristal Delivery

Het aan LIOF gelieerde Nedermaas Ventures en het Innovatiefonds van de Provincie Limburg hebben een aandeel genomen in de farmaceutische onderneming Cristal Delivery BV. Dit jonge bedrijf ontwikkelt verbeterde producten van diverse geneesmiddelen en zal als onderdeel van deze financiering vanuit Utrecht verhuizen naar het Biopartner gebouw op de Maastricht Health Campus. Tevens zal het […]

Cristal Delivery wint Utrechtse Ster 2012

Cristal Delivery uit Utrecht is de winnaar geworden van de Utrechtse Ster. Dit is vandaag bekend gemaakt tijdens Innovation Day. Met deze prijs wil de Stichting Vrienden van Sonnenborgh de aandacht vestigen op projecten waarbij wetenschappelijke kennis in de regio Utrecht de basis vormt voor succesvolle bedrijvigheid. Cristal Delivery is een jong farmaceutisch bedrijf dat […]

Nanomedicijn bedrijf Cristal Delivery verhoogt de therapeutische waarde van geneesmiddelen

Cristal Delivery B.V. is een recent opgericht farmaceutisch bedrijf dat een duidelijke meerwaarde creëert voor patiënten met momenteel onderbehandelde aandoeningen. Cristal Delivery heeft zogenaamde nanomedicijnen ontwikkeld, waarbij het geneesmiddel na toediening op een langzame en gecontroleerde manier afgegeven wordt. Op deze manier zijn geneesmiddelen werkzamer, veiliger en ook gemakkelijker in gebruik. Cristal Delivery ontwikkelt een […]